The ADC targets B7-H3 on tumor cells, is internalized, and releases a topoisomerase I inhibitor that causes DNA damage and apoptosis in B7-H3–positive cells; DNA topoisomerase I is the intracellular payload target, not the antigen targeted by the drug.